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SCIENCE FOR JUDGES II
INTRODUCTION
Margaret A. Berger*
This issue of the Journal of Law and Policy contains a second
installment of articles about science-related questions that arise in
the litigation context. As previously explained, these essays are
expanded and edited versions of presentations made to federal and
state judges at programs funded by the Common Benefit Trust
established in the Silicone Breast Implant Products Liability
Litigation.1 These conferences are held at Brooklyn Law School
under the auspices of its Center for Health Law and Policy, in
collaboration with the Federal Judicial Center, the National Center
for State Courts, and the National Academies of Science=s Panel on
Science, Technology and Law. Science for Judges II focused on
two principal topics: (1) the practice of epidemiology and its role
in judicial proceedings; and (2) the production of science through
the regulatory process of administrative agencies.
Epidemiology has played a significant role in toxic tort actions
in proving causation, often the most crucial issue in dispute. A
failure to prove causation means a victory for the defense. Many
courts consider epidemiologic evidence the “gold standard” of
proof, and some judges go so far as to hold that a plaintiff cannot
prevail in proving causation in the absence of confirmatory
epidemiologic studies.2 The three papers on epidemiology by
* Suzanne J. and Norman Miles Professor of Law, Brooklyn Law School.
Professor Berger is the Director of the Science for Judges Program.
1
See Margaret A. Berger, Introduction, Science for Judges, 12 J. L. &
POL’Y 1 (2003).
2
See, e.g., Wade-Greaux v. Whitehall Labs., Inc., 874 F. Supp. 1441, 1480
(D.V.I. 1994).
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extremely well-credentialed scientists should therefore be of
considerable interest to anyone concerned with toxic tort litigation.
The first, by Professor John Concato of the Yale University School
of Medicine, provides an overview of different research designs
that epidemiologists employ in conducting studies. The second, by
Professors Joseph Lau and John Ioannidis of the Tufts-New
England Medical Center, discusses how and when multiple
epidemiologic studies can be combined. The final paper by
Professor James Robins of the Harvard School of Public Health
expresses skepticism about hinging compensation in toxic tort
actions on proof of causation derived from epidemiologic data.
The second set of papers deals with science produced by
administrative agencies. An introductory comment by Professor
Richard Merrill of the University of Virginia Law School explains
that both the Federal Drug Administration (FDA) and the
Environmental Protection Agency (EPA)—which are responsible
for regulating the great majority of products that become the
subject of toxic tort litigation—require scientific studies and make
scientific assessments in the course of their work. The science that
is produced may subsequently become relevant in court
proceedings when, for instance, a plaintiff claims that taking a drug
approved by the FDA caused adverse health effects. Papers by Dr.
Michael Friedman, formerly with the FDA, and Robert Sussman,
Esq., formerly with the EPA, discuss the respective roles of these
agencies in creating scientific information. Professor Wendy
Wagner of the University of Texas Law School writes of a
relatively new phenomenon: the importation into regulatory
decision-making of a new approach that has its roots in the
Daubert3 test used by federal courts in determining the
The notion that one can accurately extrapolate from animal data to
humans to prove causation without supportive positive epidemiologic
studies is scientifically invalid because it is inconsistent with several
universally accepted and tested scientific principles.
Id.
3

In Daubert v. Merrrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993),
the first of the Supreme Court=s recent cases on the admissibility of expert
testimony, the Court imposed an obligation on federal district judges to screen
scientific opinions proffered by an expert to ensure scientific reliability before
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admissibility of expert testimony. In the final paper, Professor
Sheila Jasanoff of the John F. Kennedy School of Government at
Harvard University and Dogan Parese provide a comparative
perspective by contrasting the policies that drive the treatment of
asbestos claims in the United States with those that lead Great
Britain and the Netherlands to manage the compensation of
asbestos victims through administrative rather than judicial
processing.
These brief descriptions of the papers contained in this issue of
the Journal provide a glimpse of the complexity and importance of
the scientific and policy issues that courts encounter when
handling toxic tort litigation. It is the hope of the organizers of the
Science for Judges programs that these papers will prove useful to
judges and lawyers who deal with the daunting questions that arise
at the intersection of science and the law.

allowing the expert to testify.

